New treatments for Alzheimer’s are on the market, but the price tag is making them inaccessible. The new treatments are not covered by Medicare or Medicaid, which is something the Alzheimer’s Association is trying to change.
INDIANAPOLIS — 110,000 Hoosiers currently live with Alzheimer’s. That number is expected to grow to 130,000 by 2025.
“There are two drugs that are currently on the market. One is called Aduhelm and the other is Leqembi,” David Sklar, Director of Government Affairs at the Alzheimer’s Association Greater Indiana Chapter, said.Darlene Bradley has been living with Alzheimer’s for six years. She knows first-hand how these new treatments work.
Bradley wants to go back on the treatment, but price tag of over $20,000 makes it next to impossible to get. “It’s unprecedented. There have been no other drugs and certainly no other disease where drugs have not been covered by CMS if FDA approved,” Sklar said. “This is kind of a problem of their own creation. We are really asking them to fix it and cover these drugs.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Medicare Trustees Report for 2023 contained no bad newsExpenditures remain high -- primarily due to high healthcare costs, not program generosity
Read more »
Merck sues Biden administration over Medicare drug price negotiationsIn a scathing complaint filed in federal district court, Merck excoriated the Medicare price negotiation process as a 'sham' and 'tantamount to extortion.'
Read more »
Merck sues HHS over drug negotiation, claims program ‘tantamount to extortion’In its suit, the drug giant claims that Medicare negotiation program is unconstitutional
Read more »
N.J. drugmaker sues federal government, calling plan to negotiate Medicare drug prices ‘extortion’The company is seeking to halt the program, which is expected to save taxpayers billions of dollars in the coming years.
Read more »
Merck sues U.S. government to halt Medicare drug price negotiationMerck says it sued the U.S. government, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act.
Read more »
Merck sues feds, calling plan to negotiate Medicare drug prices ‘extortion’The drugmaker said in a complaint filed Tuesday that the program does not involve genuine negotiation.
Read more »